| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15171 R62285 |
Benevent - SNRI, 2023 | Digestive system anomalites | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: SNRI only | 2.99 [0.42;21.39] C | 1/314 157/146,855 | 158 | 314 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11684 R42942 |
Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 | Digestive system malformation | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
1.25 [0.79;1.99] excluded (control group) |
24/1,438 77/5,751 | 101 | 1,438 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11685 R42958 |
Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 | Digestive system malformation | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.60 [0.84;3.05] | 24/1,434 15/1,435 | 39 | 1,434 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11745 R43134 |
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 | Gastrointestinal malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.86 [0.48;1.55] excluded (control group) |
-/2,532 -/- | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11746 R43148 |
Huybrechts - Duloxetine (Controls unexposed, sick), 2020 | Gastrointestinal malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.67 [0.31;1.45] | -/2,532 -/2,456 | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11696 R43028 |
Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 | Digestive system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.89 [0.44;1.83] | -/738 -/14,847 | - | 738 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.08 [0.66;1.78] | 197 | 5,018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 11745, 11684